bbT369

bbT369 is an investigational autologous CAR T cell therapy designed for the treatment of relapsed and/or refractory B cell non-Hodgkin lymphoma (B-NHL). It is a next-generation, dual-targeted (CD79a and CD20) gene-edited product that uses a single lentiviral vector to express chimeric antigen receptors against both antigens. The therapy incorporates split co-stimulatory domains (CD28 and 4-1BB) to enhance T cell activation and includes a gene edit that knocks out CBLB—a negative regulator of T cell function—using an mRNA encoding the CBLB-targeting megaTAL enzyme. This design aims to overcome resistance mechanisms seen with prior CD19-directed CAR T therapies by limiting antigen escape, enhancing expansion/persistence of CAR-T cells, and maintaining potency in immunosuppressive environments. bbT369 is currently being evaluated in phase 1/2 clinical trials for various subtypes of relapsed/refractory B-NHL including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), follicular lymphoma grade 3b, and transformed follicular lymphoma[1][4][5][6][8].

Other names

anti-CD79a & CD20 dual CAR T cell therapyautologous anti-CD79a/anti-CD20 CAR T cells